FibroNox is focused on developing patented first-in-class therapeutics to treat and reverse life-threatening fibrotic diseases. FibroNox has pioneered the development of selective Nox4 inhibitors and Nrf2 activators that have shown robust protection from fibrosis development and promoted the reversal of age-associated established fibrosis. FibroNox’s initial focus is treating idiopathic pulmonary fibrosis and fibrosis in Duchenne muscular dystrophy. FibroNox’s therapeutics offer the opportunity to reverse age-associated established fibrosis, representing the holy grail for more effective strategies to treat fibrotic diseases.
| Website | http://www.fibronox.com |
| Employees | 2 (1 on RocketReach) |
| Founded | 2023 |
| Industry | Biotechnology Research |
| Keywords | First-In-Class Drugs, Tissue Repair, Regenerative Medicine, Oxidative Stress Reduction, Innovative Therapies, Drug Development, Clinical Trials |
Looking for a particular FibroNox, Inc. employee's phone or email?
FibroNox, Inc. Questions
Joseph Patti is the President and Chief Executive Officer, Executive Director of FibroNox, Inc..
1 people are employed at FibroNox, Inc..
Top FibroNox, Inc. Employees
